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Abstract
The basis of severe malaria pathogenesis in part includes sequestration of Plasmodium falciparum-infected erythrocytes (IE)
from the peripheral circulation. This phenomenon is mediated by the interaction between several endothelial receptors and
one of the main parasite-derived variant antigens (PfEMP1) expressed on the surface of the infected erythrocyte membrane.
One of the commonly used host receptors is ICAM-1, and it has been suggested that ICAM-1 has a role in cerebral malaria
pathology, although the evidence to support this is not conclusive. The current study examined the cytoadherence patterns
of lab-adapted patient isolates after selecting on ICAM-1. We investigated the binding phenotypes using variant ICAM-1
proteins including ICAM-1Ref, ICAM-1Kilifi, ICAM-1S22/A, ICAM-1L42/A and ICAM-1L44/A using static assays. The study also
examined ICAM-1 blocking by four anti-ICAM-1 monoclonal antibodies (mAb) under static conditions. We also characterised
the binding phenotypes using Human Dermal Microvascular Endothelial Cells (HDMEC) under flow conditions. The results
show that different isolates have variant-specific binding phenotypes under both static and flow conditions, extending our
previous observations that this variation might be due to variable contact residues on ICAM-1 being used by different
parasite PfEMP1 variants.
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Introduction
Malaria is still a life-threatening disease despite the huge effort
to eliminate it. WHO estimated about 207 million cases of
malaria, and 627 000 fatalities reported in 2012, with most of these
occurring in African children under five years old [1]. Malaria
severe disease syndromes such as cerebral malaria (CM) are
thought to involve the adhesion between the parasite derived
antigens and a subset of host receptors [2].
The mature stages of the asexual intraerythrocytic cycle of
Plasmodium falciparum are not found in the circulation due to
their ability to localise to different organs in a phenomenon known
as sequestration. Understanding some of the key events that
facilitate sequestration is important to identify possible targets to
develop either inhibitors or vaccines [3]. Plasmodium falciparum
erythrocyte membrane protein-1 (PfEMP-1) [4–6] mediates
sequestration with various human receptors [3] including
ICAM-1 [7] and CD36 [8,9] and EPCR [10].
One of the commonly used receptors, ICAM-1, has a
cytoplasmic tail, a transmembrane domain and five extracellular
Ig-like domains [11,12]. The main function of ICAM-1 on
endothelial cells is to allow leukocyte transmigration from the
blood to the tissues in inflammatory sites upon cytokine
stimulation. ICAM-1 binds to leukocyte receptors such as
leukocyte function-associated antigen (LFA-1) or macrophage-1
antigen (Mac-1). In addition, ICAM-1 mediates binding to
pathogens, such as human rhinoviruses (HRVs) [12], and P.
falciparum infected erythrocytes [7]. The ICAM-1 binding sites
for IE, rhinoviruses, LFA-1 and fibrinogen are overlapping, but
also have distinct regions [13,14].
Several lines of evidence support the involvement of ICAM-1 in
malaria pathogenesis. First, a study carried out on post-mortem
samples taken from people diagnosed with CM showed accumu-
lation of IE in brain vessels that co-localised with ICAM-1 [15]. In
addition, ICAM-1 was found up-regulated in brain accompanied
with P. falciparum infection [16]. Isolates from severe malaria
patients and particularly from CM demonstrated higher binding to
ICAM-1 [10,17,18], although this is not seen in all studies.
Another line of evidence is the association between CM and a
homozygous mutation in ICAM-1 in Kilifi, Kenya, named ICAM-
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1Kilifi [19], although it should be noted that other studies such as
those in the Gambia and Thailand have not shown an association
between ICAM-1Kilifi and severe malaria [20,21] [12]. In contrast,
ICAM-1Kilifi was suggested to have a protective role in Gabon
[22]. Previous studies have characterised ICAM-1 binding
phenotypes under both static and flow conditions on purified
proteins and endothelial cells. These have shown that IE have
subtle differences in binding to ICAM-1 with different affinities
and avidities ranging from 2.8 nM to 144 nM for a number of
PfEMP1 variants from the IT lineage [23].
CD36 is an integral membrane protein expressed on various
host cells including endothelium, and platelets [3]. CD36 is
implicated in the regulation of membrane transport systems,
immune responses in humans [24,25] and platelet adhesion [26].
CD36 is a common receptor for almost all P. falciparum isolates in
field studies, albeit with some notable exceptions. Adhesion to
CD36 is seen for IE from severe or uncomplicated malaria patients
[17,27] except isolates from pregnancy-associated malaria [28,29],
although in some studies it has been associated with uncompli-
cated malaria isolates [9]. Also, CD36 adhesion protects from CM
in South East Asia [30]. Recently, it has been suggested that CD36
may protect against anaemia caused by malaria [31].
PfEMP-1 proteins are encoded by 50–60 extremely variable var
genes per parasite genome [32]. Despite this variation of the var
genes, they can be grouped into three major groups; A, B, and C
based on their promoter sequence and chromosomal locations
[33,34]. Group A var genes are less diverse than the others and
have been found to be associated with severe malaria [35]. A
typical PfEMP-1 structure consists of two to seven Duffy-binding–
like (DBL) domains and one to two cysteine-rich interdomain
region (CIDR) domains [32]. Specific domains have been
implicated in binding to certain host receptors [36]. A recent
sub-classification for DBL and CIDR domains from seven
genomes has led to the identification of shared combinations of
short tandem domain cassettes (DCs) in many different parasite
strains [37]. Among the Group A PfEMP-1 s, there are several
ICAM-1– binding DBL domains isolates identified so far,
including PFD1235w, Dd2var32 [35] and PF11_0521 [38,39].
Furthermore, from these isolates, it was possible to identify a novel
tandem three-domain PfEMP1 region called DC4, and antibodies
to this region have been found to be cross-reactive with group A
PfEMP1 proteins that bind to ICAM-1 [40]. However, although
DC8 and DC13 cassettes found in Group A PfEMP1 proteins
were associated with SM [41–43], IE expressing DC8 and DC13
were found not to bind to ICAM-1 [41,43].
In the current study, we have investigated the binding
phenotypes for ICAM-1-selected, recently lab-adapted patient
isolates under static and flow adhesion assays. We analysed the
role of four mutant ICAM-1 variants that have previously shown
different effects on laboratory isolates [44] and the effect of four
anti-ICAM-1 mAb using static assays, expanding the number of
the isolates in comparison with previous studies. Understanding
key events in cytoadherence is important in identifying possible
targets in order to develop either effective inhibitors or vaccines.
Methods
Parasite culture
Laboratory lines, ItG [45] and A4 [14] and lab-adapted patient
isolates PO-69, 8206, 8146, 8131, 6392 (from Kenya) J1, PCM-7,
BC-12 and GL-6 (from Thailand [46]) were cultured at 1%
haematocrit in O+ human erythrocytes using standard culturing
techniques, [47] using complete medium (RPMI 1640 medium
supplemented with 37.5 mM HEPES, 7 mM D-glucose, 6 mM
NaOH, 25 mg/ml of gentamicin sulphate, 2 mM L-glutamine,
and 10% human serum) at a pH of 7.2 in a gas mixture of 96%
nitrogen, 3% carbon dioxide, and 1% oxygen. A batch of parasite
stabilates selected on recombinant ICAM-1 was made to minimise
the effect of mixed populations and antigenic switching. The
parasites were used in binding assays for only three weeks post-
selection.
All patient isolates were collected with consent as part of clinical
studies in Kenya and Thailand, and all patient material has been
removed during culture, replaced with blood sourced commer-
cially from the UK Blood Transfusion Service.
ICAM-1 Selection
50 ml Protein A Dynabeads (Invitrogen) were washed 3 times
with 200 ml 1% BSA/PBS using a magnet to retain the beads each
time, and then resuspended in 200 ml PBS/1%BSA. 2.5 mg/ml
ICAM-1Ref protein was added to the bead suspension. The
mixture was rotated at 15 rpm at room temperature for
60 minutes. ICAM-1 labelled Dynabeads were purified on the
magnet, washed three times in 1% BSA/PBS, and resuspended in
200 ml 1% BSA/PBS. Parasite culture was enriched for mature
stages using Plasmion by standard protocols [12]. The enriched IE
were incubated with ICAM-1 labelled Dynabeads and rotated for
45 minutes at room temperature. Unbound parasites were
removed by three gentle washes with 1% BSA/PBS. IE-bound
beads were resuspended in complete media with fresh washed red
blood cells and cultured as standard.
Parasite genotyping
Genotyping was carried out to ensure the distinctiveness of each
isolate in this study and that cross contamination of parasite
cultures had not occurred. The primers and reactions used were
based on the Recommended Genotyping Procedures (RGPs) to
identify parasite populations (Medicines for Malaria Venture,
Amsterdam May 2007). The protocol was accessed through
http://www.who.int/malaria/publications/atoz/rgptext_sti.pdf.
DNA was extracted at trophozoite stage then purified using
QIAamp DNA Blood Mini Kit (QIAGEN).
Recombinant proteins
ICAM-1-Fc reference (ICAM-1Ref [48]), ICAM-1 Kilifi (ICAM-
1Kilifi), ICAM-1 S22/A (ICAM-1S22/A), ICAM-1 L42/A (ICAM-
1L42/A) and ICAM-1 L44/A (ICAM-1L44/A) [44] have been
described previously.
Static adhesion assays
Purified recombinant proteins were spotted in triplicate in a
radial pattern using 2 ml spots on 60 mm plastic petri dishes
(Falcon 1007; Becton Dickinson, Oxford, UK) at concentrations of
50 mg/ml for ICAM-1, two plates were prepared for each parasite
isolate. The dishes were incubated in a humidified chamber for 2
hours at 37uC to allow the proteins to adsorb to the surface, after
that the spots were aspirated off and the plastic petri-dishes were
filled with 1% BSA/PBS, blocking buffer, and incubated overnight
at 4uC. The plates were warmed at 37uC for one hour prior the
assay. IE were suspended in binding buffer (RPMI 1640 R4130
(Sigma, Dorset, UK) in 2% glucose at pH 7.2) at 3% parasitemia
and 1% haematocrit. The blocking buffer was removed from the
dish prior to adding 1.25 ml of the IE suspension. The plates were
incubated at 37uC for one hour with gentle resuspension every
10 minutes. Then, the IE suspension was removed by gentle
manual washing (4–6 washes) with binding buffer medium. The
bound IE were fixed with 1% glutaraldehyde in PBS for 1 hour
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and stained with 10% Giemsa for 20 minutes. Six pictures were
captured for each spot under 900x magnification using software
HC Image (Sewickley, USA) to give 18 readings per plate for each
isolate and in total 36 readings from the two plates. The pictures
were analysed by Image-Pro version 7 (Rockville MD, USA). The
means of at least three independent experiments performed on
different days were calculated using Microsoft Excel 2010. The
results were expressed as the mean number of IE bound per mm2
of surface area or, when appropriate, as a percentage of the
control binding for the mutant ICAM-1s and mAbs inhibition
data.
Static inhibition assays
The same static binding technique described above was applied
with the addition of mAbs at 5 mg/ml to the IE suspension prior
adding it to the plates. All the mAbs were commercially available;
15.2 (AbD serotec), My13 (Invitrogen), 8.4A6 (Sigma), BBIG-I1
(R&D systems).
Flow assay
HDMEC culture. HDMEC cells were obtained from Pro-
mocell (C-12210). HDMEC media (Promocell C-39220, 500 ml)
was supplemented with EC growth media (Promocell C-39215).
Sub-culturing followed the standard protocol following manu-
facturer’s instructions. Cells were washed with HEPES-buffered
Balanced Salt Solution), trypsinised and neutralised. However, for
the flow assay Accutase (Sigma) was used as an alternative
detaching reagent instead of trypsin.
VenaEC preparation. Details about the system can be found
on the Cellix website via: http://www.cellixltd.com/. TheVena-
Flux is a semi-automated microfluidic system able to perform cell
adhesion studies under shear flow mimicking in vivo flow rates. It
is designed to facilitate the study of cell adhesion, and to be more
physiologically relevant than static assays. Its construction makes it
easier to use than previous systems used to mimic physiological
rates of flow in vessels for P. falciparum adhesion studies. The
system includes VenaEC 8-channels designed for growth of
human endothelial cells with continuous feeding during the
experiment and parameters that can be adjusted and monitored
during the experiment through the VenaFlux software.
VenaEC 8-channells (Cellix - Dublin, Ireland) were coated with
12 ml of 100 mg/ml fibronectin and incubated in a humidified
petri-dish at 4uC overnight. Cells were activated with 10 ng/ml
TNF 16–24 hours before the day of the assay. On the following
day, VenaEC 8-channels were warmed at 37uC for 30 minutes.
The endothelial cells (EC) were treated with Accutase, detached
and then neutralised with medium. The EC were pelleted at
3006g for 3 minutes and resuspended in an appropriate volume
EC medium to achieve 1.56106 cells/ml. Then, 5 ml of this
suspension were seeded onto each channel and incubated at 37uC.
Once the cells attached to the channels, they were fed every
30 minutes until the EC become confluent, usually within 2–3
hours. The IE suspension for both binding and inhibition assays
was prepared as described in static assays except the haematocrit
was adjusted to 2%.
The assay was run following the Cellix protocol using the
VenaFlux software. VenaEC 8-channels were connected to Cellix
system in a microscope stage enclosed within a plastic chamber to
keep the temperature at 37uC. The flow through the channels was
adjusted to run 0.04 Pa and the IE suspension was drawn through
the channel for five minutes. After that, binding buffer was passed
through the cell at the same rate to wash for two minutes. The
bound IE were counted in six fields and converted to the number
of IE/mm2. For binding inhibition, all mAbs were used at 5 mg/
ml. The IVC7 anti-CD36 mAb was kindly provided by Prof. Ellen
van der Schoot (Sanquin, Amsterdam).
Ethics Statement
The parasites were derived from two main sources. The
collection of the Kenyan patient isolates and use in adhesion
assays was approved by the Research Ethics Committees at
KEMRI, Kenya and the Liverpool School of Tropical Medicine
[18]. The Thai isolates were originally derived from patients from
the Thai-Cambodia and Thai-Myanmar borders and were
supplied for this study from Thammasat University as laboratory
adapted isolates [46].
Results
Binding to ICAM-1Ref
All isolates were genetically distinct as shown by genotyping
(data not shown). Based on the level of binding to ICAM-1Ref, all
the isolates were categorised into high and low-avidity parasites.
ItG was previously defined as a high-avidity ICAM-1 binder
whereas, A4 was characterised as low-avidity ICAM-1 binder from
an earlier study [49]. Using the same criteria only two of the lab-
adapted isolates were high-avidity ICAM-1 binders; 8146 and
8206. The rest of the isolates were assigned as low-avidity binders
(Figure 1A).
Binding to mutant ICAM-1 proteins
The current study showed that there were considerable
differences in IE binding to mutant ICAM-1 proteins (Figure 1).
The S22/A mutation severely reduced the binding of the high-
avidity group and some of the low-avidity isolates; 6392, and GL6
by about 80%. In addition, there was a moderate effect on PO69,
BC12 and J1 (Figure 1B). On the other hand, L42/A mutation
showed a critical effect on all of the isolates, reducing binding by at
least 50% compared to ICAM-1Ref, with the binding almost totally
inhibited for most of isolates, including the high-avidity group
(Figure 1C). By contrast, L44/A mutation reduced the binding of
GL6 only, and increased the binding for some isolates (Figure 1D).
The binding of isolates was variably disturbed by the ICAM-1Kilifi
polymorphism. ICAM-1Kilifi affected the binding of four isolates
by about 50%. Moreover, there were three isolates was reduced by
more than 75%, PCM7, 6392 and 8131. Whereas, the ItG and
PO69 isolates was only reduced by 20%. Statistical tests
comparing low and high avidity isolates did not show a significant
difference between these populations, although this was highly
affected by the small number (n = 3) of high avidity isolates
available (Figure 1E).
ICAM-1 Static Inhibition Assays
The effect of anti-ICAM-1 mAbs on the binding of IE to
purified ICAM-1 under static conditions has been studied using
specific mAbs reacting with epitopes on Ig-like domains 1 and 2.
MAbs 15.2, BBIG-I1 and My13 mapping to domain 1, and 8.4A6
mAb mapping to domain 2 were used in a study that differentiated
between the binding sites on ICAM-1 for IE and LFA-1 [13].
Figure 2 (and Data S2) show that different mAbs have different
inhibitory effects on the isolates. The results are expressed as the
percentage of the binding of each isolate against its binding to
ICAM-1Ref. The binding of most of the isolates was reduced by
about 75% by two mAbs 15.2 and My13. However, there was only
40% inhibition caused by 15.2 and My13 to PO69 (Figure 2A–B).
The inhibition caused by 8.4A6 was different. The effect varied
between 25–50% for most of the isolates, although there was no
effect by 8.4A6 on the ItG and 8206 isolates (Figure 2C). The
ICAM-1 Binding Variation in P. falciparum Patient Isolates
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Figure 1. Static adhesion assay, 2 ml spots at 50 mg/ml protein concentration were placed onto 6 cm dishes and standard protein
static binding assays carried out with IE suspended in binding buffer at a parasitaemia of 3% and a haematocrit of 1%. The results
show the mean of binding (IE/mm2) (Figure 1A) and %ICAM-1Ref binding (Figure 1B–E), and the bars represents SE (n$3).
doi:10.1371/journal.pone.0111518.g001
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range of inhibition for BBIG-I1 was between 25%–75% for nearly
all isolates except there was almost no effect on 8206 (Figure 2D).
These variations again suggest the use of variable contact residues
between ICAM-1 and variant PfEMP-1 proteins.
Flow endothelial adhesion assay
The binding level on HDMEC under flow conditions is similar
for seven out of eleven isolates tested within the range 200–300
IE/mm2 (Figure 3 and Data S3). In contrast, two isolates, 8146
and J1, bound within the range 600–700 IE/mm2 to HDMEC
despite J1 being assigned as low-avidity ICAM-1 binder on
purified ICAM-1. Another two isolates, 8206 and 8131, showed
relatively less binding to HDMEC although 8206 was categorised
as a high-avidity ICAM-1 binder on purified ICAM-1. Further
investigation using an anti-ICAM-1 mAb revealed similar activity
for 15.2 mAb on almost all isolates, reducing binding by
approximately 50% (Figure 3B). However, the binding was
reduced by about 80% for eight isolates in the presence of the
anti-CD36 mAb and for the other three was reduced by about
60% (Figure 3C).
Discussion
The aim of this study was to establish the binding characteristics
of a set of new ICAM-1 binding isolates to provide further
information about the interaction between ICAM-1 and PfEMP-1.
The purpose of using field isolates is usually to investigate the
association between binding phenotypes and clinical outcomes.
The selection of ICAM-1 binding PfEMP-1 populations in this
study introduces bias by potentially expanding small sub-popula-
tions from the original sample and so cannot be used to derive
associations between the clinical outcomes and binding pheno-
types. Our original study used three genetically distinct ICAM-1-
binding laboratory isolates (two of which (ItG and A4) are included
in this work for comparison), screened against 25 mutant ICAM-1
proteins using static and flow adhesion systems [44].
Based on this previous work, binding and inhibition assays were
run on a larger number of recently lab-adapted isolates using the
ICAM-1 mutations previously shown to disrupt the binding and
discriminating between laboratory isolates, using static assays only.
Binding to endothelial cells was investigated using a flow adhesion
system.
Alanine replacement mutagenesis and ICAM-1-specific mAbs
have given more details about the binding region on ICAM-1 for
P. falciparum-infected erythrocytes. The binding between IE and
ICAM-1 was revealed to involve the BED face of ICAM-1,
including the DE loop [44]. The binding phenotypes from
previous studies were categorised based on the isolate’s avidity to
ICAM-1. Overall, the new binding and inhibition data support the
original findings that different ICAM-1-binding isolates can use
different contact residues in the DE loop of ICAM-1 to bind.
Figure 2. Static adhesion assay. The same method as for Fig. 1 but with the addition of 5 mg/ml ofmAbs 15.2 (A), My13 (B), 8.46A (C) and BBIG-I1
(D) prior the IE incubation with ICAM-1Ref. The results show the percentage of binding in the presence of ICAM-1 mAb compared to the no mAb
treatment (A), and the bars represents SE (n.3).
doi:10.1371/journal.pone.0111518.g002
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Moreover, current data support previous findings by demonstrat-
ing a significant role for L42 for all ICAM-1-binding isolates.
Two ICAM-1-specific mAbs My13 and 15.2, which have been
mapped to epitopes including the L42 residue, reduced the
binding of all the isolates. The binding of low-avidity-ICAM-1
isolates was more affected by these mAbs than high-avidity-
ICAM-1 parasites. 8.4A6 ICAM-1 mAb, which targets an epitope
on domain 2, can also inhibit the binding of all isolates. This might
be explained by the epitope in domain 2 being in a position close
to domain 1 or affecting the structure of this domain, as they have
been shown to interact to produce the native ICAM-1 structure
[13]. Interestingly, most of the isolates were low-avidity ICAM-1
binders similar to A4, which was previously associated with a
signature that reflects isolates from SM cases [18].
Flow adhesion on endothelial cell assays more accurately
resembles the situation seen in the human circulation than static
assays [12]. In the present study, we used TNF-activated
HDMEC, which expresses both ICAM-1 and CD36 receptors as
well as other endothelial receptors, using the Cellix system to
measure IE adhesion. The Cellix system has produced comparable
results with earlier flow-based systems on various endothelial cells
(data not shown). The binding to activated HDMEC was
approximately the same level for most (7/11) isolates, comparable
to ItG and A4, which bind in the range 200–300 IE/mm2. The
binding was reduced with both anti-ICAM-1 and anti-CD36
mAbs with the latter causing greater inhibition than anti-ICAM-1.
Binding to CD36 is shown in Data S1. This might be explained by
‘receptor co-operation’ between ICAM-1 and other receptors
[12,50]. It is likely that ICAM-1 is not the only receptor involved
in CM pathogenesis and, for example, a recent study has
associated the ability of IE to bind to EPCR with severe malaria,
including CM [10,51].
ICAM-1 has been suggested to play a capturing role from the
circulation thereby contributing to the pathogenesis of CM [49].
Figure 3. Flow endothelial cell adhesion assay. HDMEC seeded on channels pre-coated with fibronictin; IE were passed on confluent cells for
five minutes followed by washing by binding buffer for two minutes before counting 6 fields in two different channels. The parasitaemia was 3% and
a haematocrit of 2%. The results show the mean of binding with no inhibitory mAbs (A) and the % binding on treatment with 5 mg/ml of 15.2 anti-
ICAM-1 (B) and 5 mg/ml IV-C7 anti-CD36 (C) mAbs compared to no mAb treatment. The bars represents SE (n$3).
doi:10.1371/journal.pone.0111518.g003
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However, the role of CD36 in sequestration is not understood.
CD36 binding is a characteristic phenotype for the majority of
paediatric isolates and in some studies has been shown to be more
associated with adhesion to isolates from UM cases. It has been
suggested that the host utilises CD36 to control the parasitemia
prior to host immune responses or to minimise pro-inflammatory
responses [18].
The molecular basis of the variable binding to ICAM-1 is
thought to be due to differences in the contact residues between
this receptor and the variant PfEMP1s. PfEMP-1 binds to ICAM-
1 through a diverse set of DBLb domains mainly from groups B or
C and it would be difficult to target DBLb domains in these groups
due to their extensive sequence diversity. This is seen particularly
in approaches to discriminate ICAM-1 binding DBLb domains
from non-binding ones, which has only been partially successful
[52]. There are ICAM-1 binders among the group A PfEMP-1
that contain a definable DC4 cassette [40], but this is still at a very
preliminary stage and needs more investigation to see if it could
provide a starting point for the development of a vaccine targeting
CM by inhibiting IE sequestration via ICAM-1 in the brain. The
variability in the binding characteristics between IE and ICAM-1
suggests that it could be a difficult problem to find a cross-blocking
therapy, although the central role of the L42 residue and anti-DC4
blocking antibodies provides some support for this approach.
The divergent binding pattern to variants of ICAM-1 of
different IE is similar to that demonstrated by the causative agent
of the common cold, Human Rhinovirus (HRV). The major
serotypes of HRV utilise ICAM-1 to invade the epithelium and
two different HRV serotypes have shown varying adhesion
phenotypes to ICAM-1Ref and ICAM-1Kilifi, and their association
with varying clinical outcome [53]. Very recently, an anti-human
ICAM-1 antibody that specifically binds domain 1 of human
ICAM-1, prevented entry of two major groups of rhinoviruses,
reduced virus burden, cellular, inflammation and pro-inflamma-
tory cytokine induction in vivo. Importantly, this antibody did not
affect ICAM-1 binding to LFA-1, leaving this critical host pathway
intact [54]. Similar approaches could be used to lead to the
development of novel treatments candidates to reduce malaria
morbidity and mortality but require a good understanding of the
variety of IE adhesion to ICAM-1.
The key outcome of this study is the identification of vital targets
on the sites of the interaction between parasite ligands and host
receptors, which may lead to the development of inhibitors which
target IE sequestration. Despite the presence of rapid and effective
parasite-killing drugs, deaths still occur among children with
severe malaria complications, particularly in the immediate period
after admission to hospital. Several strategies to improve survival
in malaria have been highlighted in a recent review [55]. One of
these is targeting parasite adhesion to the vascular endothelium.
Anti-adhesion therapeutics is an encouraging project in the
discovery of novel treatments, including compounds based on
the structure of endothelial receptors [56]. High-throughput
screening could identify adhesion blocking molecules that inhibit
IE from binding or activating microvascular endothelium [55]. An
example of this type of rational-inhibitor design is (+)-EGCG, a
polyphenol compound showing significant inhibition ranging from
37%–80% by the new ICAM-1-binding isolates used in the
present study [57]. The variation of inhibition by (+)-EGCG might
be due to the variable contact residues on PfEMP-1 of different
patient isolates. The mode of action of (+)-EGCG is assumed to be
its structural simulation of part of the ICAM 1 binding site for IE
based around the L42 loop.
In conclusion, the isolates tested use variable contact residues on
ICAM-1 for their binding. However, L42/A inhibits all isolates
binding, supporting the idea of a conserved region on ICAM-1 for
PfEMP-1 binding and that could be used to target interventions.
Supporting Information
Data S1 Adhesion data of P. falciparum isolates on
ICAM-1 variants under static adhesion assays. Numbers
represent the means of adherent IE/mm2 in independent
experiments and the % compared to ICAM-1Ref binding for the
mutant ICAM-1 proteins. Data for binding to CD36, where
available, is also provided (means and SD, NA: no data available).
(XLSX)
Data S2 Inhibition data of P. falciparum isolates under
static inhibition assays. Data represents the means of the
binding in the presence and absence of mAbs in independent
experiments and the % of the binding in the presence of mAbs
compared to no mAb binding. It should be noted that the numbers
expressed here are/field and not/mm2.
(XLSX)
Data S3 Adhesion data of P. falciparum isolates to
HDMEC under flow adhesion assays. Data represents the
means of independent experiments/mm2 and their standard
deviation and number of experiments for each isolate.
(XLSX)
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